Smart purchase by Loblaw

Article Excerpt

LOBLAW COMPANIES LTD. $33 (Toronto symbol L; Conservative Growth Portfolio, Consumer sector; Shares outstanding: 281.4 million; Market cap: $9.3 billion; Price-to-sales ratio: 0.3; Dividend yield: 2.5%; TSINetwork Rating: Above Average; www.loblaw.ca) is buying most of the Zellers department store chain’s prescription drug accounts. U.S.-based Target Corp. (New York symbol TGT) recently acquired over 220 Zellers stores as part of its plan to expand into Canada. However, it will take Target several months to renovate these locations. As a result, Target decided not to take over Zellers’ drug business and will instead open its own pharmacies in these stores. Loblaw will pay $35 million for the Zellers accounts. That’s equal to 5% of its 2011 earnings of $769 million, or $2.73 a share. Selling drugs is more profitable than sales of food or general merchandise, so these new accounts should boost Loblaw’s earnings. The purchase will also draw more traffic to Loblaw’s stores. Loblaw is a buy. buy…